Human BioSystems
OTC Bulletin Board : HBSC

Human BioSystems

April 23, 2007 07:00 ET

Human BioSystems Appoints New Member to Its Advisory Board

PALO ALTO, CALIFORNIA--(CCNMatthews - April 23, 2007) - Human BioSystems ("HBS")(OTCBB:HBSC), a developer of preservation platforms for donor organs, blood platelets and other biomaterials announced today that it has appointed Wan Hee Kim, Ph.D. to the Company's Advisory Board.

"I am pleased to announce that Dr. Kim has accepted this appointment to our Advisory Board," stated Harry Masuda, CEO of Human BioSystems. "His acceptance comes at an opportune moment for HBS as we are seeking business partnerships for our technologies in the U.S. and abroad in countries such as Korea."

Dr. Kim is known worldwide as the "Father of Korean Electronics" and is credited with designing the National Master Plan for the development of the electronics and related industries in Korea after being called upon as a special advisor to the President of Korea. As a result of the successful execution of his plan, electronics has become the dominant industry there and his efforts have spawned many internationally known companies such as Samsung, Anan-Amkor, Daewoo and many others, which were established through Dr. Kim's help and guidance.

Dr. Kim is also a distinguished scholar in engineering education, serving 21 years at Columbia University (New York City) as a Professor of Electrical Engineering and Computer Science and has authored many books and scientific articles in that field. He is an IEEE Fellow, a John Simon Guggenheim Fellow, and the recipient of the US-Asian Achievement Medal, given to outstanding individuals in the U.S. of Asian decent.

In his role as international mediator, Dr. Kim has been called upon to broker difficult negotiations between major American and Korean companies.

"I have known Mr. Masuda for many years and look forward to working with him and HBS as a member of the Advisory Board to assist the company in the areas that I can be of help", Dr. Kim stated.

Human BioSystems is headquartered in Palo Alto, California and has research facilities in Michigan.

Certain statements contained herein are "forward-looking'' statements (as such term is defined in the Private Securities Litigation Reform Act of 1995). Because such statements include risks and uncertainties, actual results may differ materially from those expressed or implied by such forward-looking statements. Factors that could cause results to differ materially from those expressed or implied by such forward-looking statements include, but are not limited to, results from ongoing research and development as well as clinical studies, failure to obtain regulatory approval for the Company's products, if required, failure to develop a product based on the Company's technology, failure of any such products to compete effectively with existing products, the inability to find a strategic partner or to consummate a relationship with a potential strategic partner on acceptable terms, and other factors discussed in filings made by the Company with the Securities and Exchange Commission.

Contact Information